Compare Nucor Corporation (NUE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Novavax Inc — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Nucor Corporation is far larger — about 30.7× Novavax Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Novavax Inc for 59 Days on average.
| NUE | NVAX | |
|---|---|---|
Market Cap | $55.84B | $1.82B |
Volume | 848,835 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $12.75 |
52-Week Low | $131.78 | $6.22 |
Typical Hold Time | 78 Days | 59 Days |
Enterprise Value | $60.25B | $1.39B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with a moderate buy analyst consensus and a $266.88 price target. Revenue rebounded to $32.49B in 2025, though net margins have compressed from 2022 peaks. Recent news highlights steel sector volatility and Nucor's Q3 2026 guidance projecting higher earnings on improved pricing.
Outlook remains cautiously optimistic with earnings growth potential from steel price strength and operational efficiency, balanced by competitive pressures from new capacity and cyclical demand risks. The stock offers value at a P/E of 19.64 and a solid dividend history, but investors face headwinds from margin pressure and industry competition.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
